293 related articles for article (PubMed ID: 27988109)
61. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.
Yagasaki F; Wakao D; Yokoyama Y; Uchida Y; Murohashi I; Kayano H; Taniwaki M; Matsuda A; Bessho M
Cancer Res; 2001 Dec; 61(23):8371-4. PubMed ID: 11731410
[TBL] [Abstract][Full Text] [Related]
62. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes.
Fambrough D; McClure K; Kazlauskas A; Lander ES
Cell; 1999 Jun; 97(6):727-41. PubMed ID: 10380925
[TBL] [Abstract][Full Text] [Related]
63. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.
Basu D; Pal R; Sarkar M; Barma S; Halder S; Roy H; Nandi S; Samadder A
Curr Top Med Chem; 2023; 23(30):2877-2972. PubMed ID: 38164722
[TBL] [Abstract][Full Text] [Related]
64. Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo.
Lorén CE; Scully A; Grabbe C; Edeen PT; Thomas J; McKeown M; Hunter T; Palmer RH
Genes Cells; 2001 Jun; 6(6):531-44. PubMed ID: 11442633
[TBL] [Abstract][Full Text] [Related]
65. Acquired Resistance Is Oncogene and Drug Agnostic.
Doebele RC
Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
[TBL] [Abstract][Full Text] [Related]
66. Kinase domain activation through gene rearrangement in multiple myeloma.
Morgan GJ; He J; Tytarenko R; Patel P; Stephens OW; Zhong S; Deshpande S; Bauer M; Weinhold N; Schinke C; Rasche L; Bailey M; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Zangari M; van Rhee F; Mughal T; Davies FE; Walker BA
Leukemia; 2018 Nov; 32(11):2435-2444. PubMed ID: 29654269
[TBL] [Abstract][Full Text] [Related]
67. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
68. Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
[TBL] [Abstract][Full Text] [Related]
69. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks.
Wagner JP; Wolf-Yadlin A; Sevecka M; Grenier JK; Root DE; Lauffenburger DA; MacBeath G
Sci Signal; 2013 Jul; 6(284):ra58. PubMed ID: 23861540
[TBL] [Abstract][Full Text] [Related]
70. Pulling back the curtain: The hidden functions of receptor tyrosine kinases in development.
Clark JF; Soriano PM
Curr Top Dev Biol; 2022; 149():123-152. PubMed ID: 35606055
[TBL] [Abstract][Full Text] [Related]
71. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor.
Tomasson MH; Williams IR; Hasserjian R; Udomsakdi C; McGrath SM; Schwaller J; Druker B; Gilliland DG
Blood; 1999 Mar; 93(5):1707-14. PubMed ID: 10029600
[TBL] [Abstract][Full Text] [Related]
72. Receptor tyrosine kinases as target for anti-cancer therapy.
Brunelleschi S; Penengo L; Santoro MM; Gaudino G
Curr Pharm Des; 2002; 8(22):1959-72. PubMed ID: 12171522
[TBL] [Abstract][Full Text] [Related]
73. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization.
Bhattacharya P; Shetake NG; Pandey BN; Kumar A
Int J Radiat Biol; 2018 Jul; 94(7):628-644. PubMed ID: 29775397
[TBL] [Abstract][Full Text] [Related]
74. A Generalizable Optogenetic Strategy to Regulate Receptor Tyrosine Kinases during Vertebrate Embryonic Development.
Krishnamurthy VV; Fu J; Oh TJ; Khamo J; Yang J; Zhang K
J Mol Biol; 2020 May; 432(10):3149-3158. PubMed ID: 32277988
[TBL] [Abstract][Full Text] [Related]
75. Mechanisms of receptor tyrosine kinase activation in cancer.
Du Z; Lovly CM
Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
[TBL] [Abstract][Full Text] [Related]
76. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
Ghosh S; Marrocco I; Yarden Y
Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
[TBL] [Abstract][Full Text] [Related]
77. Receptor tyrosine kinase inhibitors in cancer.
Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
[TBL] [Abstract][Full Text] [Related]
78. Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.
Siveen KS; Prabhu KS; Achkar IW; Kuttikrishnan S; Shyam S; Khan AQ; Merhi M; Dermime S; Uddin S
Mol Cancer; 2018 Feb; 17(1):31. PubMed ID: 29455667
[TBL] [Abstract][Full Text] [Related]
79. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH; Lopez Rodrigo E; Picarsic J; Abramson D; Rotemberg V; De Munck S; Pannecoucke E; Lu SX; Pastore A; Yoshimi A; Mandelker D; Ceyhan-Birsoy O; Ulaner GA; Walsh M; Yabe M; Petrova-Drus K; Arcila ME; Ladanyi M; Solit DB; Berger MF; Hyman DM; Lacouture ME; Erickson C; Saganty R; Ki M; Dunkel IJ; Santa-María López V; Mora J; Haroche J; Emile JF; Decaux O; Geissmann F; Savvides SN; Drilon A; Diamond EL; Abdel-Wahab O
Nat Med; 2019 Dec; 25(12):1839-1842. PubMed ID: 31768065
[TBL] [Abstract][Full Text] [Related]
80. Mannose phosphate isomerase regulates fibroblast growth factor receptor family signaling and glioma radiosensitivity.
Cazet A; Charest J; Bennett DC; Sambrooks CL; Contessa JN
PLoS One; 2014; 9(10):e110345. PubMed ID: 25314669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
